1. Home
  2. IFF vs BIIB Comparison

IFF vs BIIB Comparison

Compare IFF & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo International Flavors & Fragrances Inc.

IFF

International Flavors & Fragrances Inc.

HOLD

Current Price

$71.00

Market Cap

18.1B

Sector

Industrials

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$187.73

Market Cap

27.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IFF
BIIB
Founded
1833
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.1B
27.1B
IPO Year
2010
1996

Fundamental Metrics

Financial Performance
Metric
IFF
BIIB
Price
$71.00
$187.73
Analyst Decision
Strong Buy
Buy
Analyst Count
13
27
Target Price
$91.00
$195.00
AVG Volume (30 Days)
1.7M
726.6K
Earning Date
05-05-2026
04-30-2026
Dividend Yield
2.25%
N/A
EPS Growth
N/A
N/A
EPS
N/A
8.79
Revenue
N/A
$9,890,600,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.93
N/A
P/E Ratio
N/A
$20.91
Revenue Growth
N/A
2.22
52 Week Low
$59.14
$110.04
52 Week High
$84.45
$202.41

Technical Indicators

Market Signals
Indicator
IFF
BIIB
Relative Strength Index (RSI) 46.07 51.94
Support Level $65.23 $170.99
Resistance Level $74.51 $191.60
Average True Range (ATR) 2.18 4.23
MACD 0.17 0.26
Stochastic Oscillator 74.26 58.41

Price Performance

Historical Comparison
IFF
BIIB

About IFF International Flavors & Fragrances Inc.

International Flavors & Fragrances is the largest specialty ingredients producer globally. It sells ingredients for the food, beverage, health, household goods, personal care, and pharmaceutical industries. The company makes proprietary formulations, partnering with customers to deliver custom solutions. Through its taste and scent segments, which each generate around 25% of profits, IFF is a leading flavor and fragrances producer. The health and biosciences business, which generates 30% of profits, is a global leader in probiotics and enzymes. The remaining profits come from the food ingredients business, which sells texturants, plant-based proteins, and other ingredients, though IFF plans to divest this business in the future.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: